Hepatitis C News and Research

Latest Hepatitis C News and Research

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Four weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve 6-month survival compared with prednisolone alone in 270 patients with severe alcoholic hepatitis, according to a study in the September 11 issue of JAMA.

11 Sep 2013

Interferon-alpha 2b and ribavirin treatment may be effective for MERS-CoV infection

Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is deadly pneumonia that has killed more than 100 people, primarily in the Middle East.

10 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Boehringer Ingelheim today announced the completion of patient enrolment for a Phase IIa clinical trial investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus infection.

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

Combination of 2 antiviral drugs improves outcome in monkey model of MERS-CoV infection

National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

10 Sep 2013

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.

9 Sep 2013

Medivir discontinues development of hepatitis B compound MIV-210 on collaboration with Daewoong

Medivir AB today announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical Co. Ltd.,.

7 Sep 2013

Medivir, Daewoong Discontinue HBV Drug Development

...

6 Sep 2013

TPMG receives AMGA Acclaim Award for transforming health care through leadership, technology

The American Medical Group Association (AMGA) today announced that the recipient of the 2013 AMGA Acclaim Award is The Permanente Medical Group (TPMG) for "Transforming Health Care through Leadership and Technology," an innovative initiative that achieves superior performance through physician leadership, advanced information technology, and a mission-driven culture of collaboration.

6 Sep 2013

Peru: Liver cancer affects young people and children who do not have related risk factors

Liver cancer is the sixth most common cancer worldwide and the third most deadly. It mainly affects men over the age of 40, most often with cirrhosis or hepatitis B or C. But in Peru, it also uncharacteristically affects young people, even children, who do not have the identified related risk factors.

5 Sep 2013

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

The hepatitis C virus hijacks the body's immune system, leaving T cells unable to function. A new study in animal models suggests that blocking a protein that helps the virus thrive could restore immune function, allowing the body to fight infection. The work, led by teams at The Research Institute at Nationwide Children's Hospital and Emory University, was published online Aug. 26 in the Proceedings of the National Academy of Sciences.

4 Sep 2013

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.

4 Sep 2013

Research findings could lead to new therapeutic approaches for liver cancer

Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.

30 Aug 2013

Opioid dependence causes greatest health burden of all illicit drugs

The first ever analysis of the global and regional prevalence of dependence upon the four major categories of illicit drugs – amphetamine, cannabis, cocaine, and opioids (such as heroin) – has revealed that opioid dependence causes the greatest health burden (overall death and illness) of all the illicit drugs. The results come from new analysis of the Global Burden of Disease Study 2010, and are published in The Lancet.

29 Aug 2013

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Treatment of chronic hepatitis C virus genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA.

28 Aug 2013

Research finding could lead to potential treatment for lymphedema

The molecule interleukin-7 is an important immune messenger protein which ensures that a sufficient number of T cells are present in our body for immune defence. Researchers from ETH Zurich have now demonstrated that IL-7 has another important function: it enhances the drainage function of lymphatic vessels, which collect fluid that has leaked out of blood vessels into the body tissue and return it to the bloodstream.

27 Aug 2013

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and diagnostics company, today announced that the Tel-Aviv Stock Exchange ("TASE") has approved the new listing of OPKO's common stock on the TASE beginning on August 21, 2013, under the ticker symbol OPK. OPKO's common stock will thereafter be listed on both the NYSE in the United States and the TASE in Israel.

19 Aug 2013

Powerful mechanism helps viruses evade body's immune response

Researchers at the Salk Institute for Biological Studies have discovered a powerful mechanism by which viruses such as influenza, West Nile and Dengue evade the body's immune response and infect humans with these potentially deadly diseases. The findings may provide scientists with an attractive target for novel antiviral therapies.

19 Aug 2013

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.

15 Aug 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Interferon-alpha 2b and ribavirin treatment may be effective for MERS-CoV infection

Roche Signs Up To $422.5M Collaboration With Inovio

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Combination of 2 antiviral drugs improves outcome in monkey model of MERS-CoV infection

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Medivir discontinues development of hepatitis B compound MIV-210 on collaboration with Daewoong

Medivir, Daewoong Discontinue HBV Drug Development

TPMG receives AMGA Acclaim Award for transforming health care through leadership, technology

Peru: Liver cancer affects young people and children who do not have related risk factors

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

Research findings could lead to new therapeutic approaches for liver cancer

Opioid dependence causes greatest health burden of all illicit drugs

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Research finding could lead to potential treatment for lymphedema

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

Powerful mechanism helps viruses evade body's immune response

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in